3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
3
Vaccines, Synthetic
2
Radiotherapy
2
nanocis
1
Wound Closure Techniques
1
Vaccines
1
Technetium-99
1
Suburethral Slings
1
Radiation
1
Papillomavirus Vaccines
1
Octreotide
1
Infracyanine green
1
Indocyanine Green
1
Fibrin Tissue Adhesive
1
Fentanyl
1
Dehydroepiandrosterone
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Vulvar Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled